JP2021184734A5 - - Google Patents

Download PDF

Info

Publication number
JP2021184734A5
JP2021184734A5 JP2021130440A JP2021130440A JP2021184734A5 JP 2021184734 A5 JP2021184734 A5 JP 2021184734A5 JP 2021130440 A JP2021130440 A JP 2021130440A JP 2021130440 A JP2021130440 A JP 2021130440A JP 2021184734 A5 JP2021184734 A5 JP 2021184734A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
cell
itr2
itr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021130440A
Other languages
English (en)
Japanese (ja)
Other versions
JP7316326B2 (ja
JP2021184734A (ja
Filing date
Publication date
Priority claimed from JP2017559315A external-priority patent/JP6929230B2/ja
Application filed filed Critical
Publication of JP2021184734A publication Critical patent/JP2021184734A/ja
Publication of JP2021184734A5 publication Critical patent/JP2021184734A5/ja
Priority to JP2023115773A priority Critical patent/JP7796702B2/ja
Application granted granted Critical
Publication of JP7316326B2 publication Critical patent/JP7316326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021130440A 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法 Active JP7316326B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115773A JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161505P 2015-05-14 2015-05-14
US62/161,505 2015-05-14
JP2017559315A JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017559315A Division JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115773A Division JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Publications (3)

Publication Number Publication Date
JP2021184734A JP2021184734A (ja) 2021-12-09
JP2021184734A5 true JP2021184734A5 (https=) 2022-01-18
JP7316326B2 JP7316326B2 (ja) 2023-07-27

Family

ID=57249066

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017559315A Active JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法
JP2021130440A Active JP7316326B2 (ja) 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法
JP2023115773A Active JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017559315A Active JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115773A Active JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Country Status (5)

Country Link
US (2) US11103597B2 (https=)
EP (1) EP3294309A4 (https=)
JP (3) JP6929230B2 (https=)
AU (3) AU2016260401B2 (https=)
WO (1) WO2016183422A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294309A4 (en) 2015-05-14 2019-01-16 St. Jude Children's Research Hospital, Inc. NUCLEIC ACID MOLECULES WITH SPACERS AND METHOD FOR USE THEREOF
CA3001594A1 (en) 2015-10-14 2017-04-20 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
US20200113972A1 (en) * 2017-04-14 2020-04-16 Rhode Island Hospital Vegf gene therapy for tendon and ligament injuries
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US20210002667A1 (en) * 2018-03-15 2021-01-07 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CA3112883A1 (en) 2018-10-25 2020-04-30 Baxalta Incorporated Aav triple-plasmid system
KR20220128607A (ko) 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. 합성 dna 벡터 및 사용 방법
CN115197967B (zh) * 2021-04-08 2023-09-15 广州派真生物技术有限公司 制备重组腺相关病毒的辅助质粒及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
AU722375B2 (en) 1996-09-06 2000-08-03 Trustees Of The University Of Pennsylvania, The Methods using cre-lox for production of recombinant adeno-associated viruses
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
US20020182595A1 (en) 2001-04-27 2002-12-05 Weitzman Matthew D. Method of identifying cellular regulators of adeno-associated virus (AAV)
US8067156B2 (en) 2001-05-31 2011-11-29 The Rockefeller University Method for generating replication defective viral vectors that are helper free
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US20040137626A1 (en) * 2002-09-26 2004-07-15 Greenville Hospital System AAV ITR-mediated modulation
WO2006036502A2 (en) * 2004-09-22 2006-04-06 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
EP2524037B1 (en) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9124527B2 (en) * 2012-08-29 2015-09-01 International Business Machines Corporation Sliced routing table management
AU2013336601B2 (en) 2012-10-26 2018-01-25 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
HK1220488A1 (zh) 2013-03-15 2017-05-05 The Children's Hospital Of Philadelphia 含有填充者/填充物多核苷酸序列的载体及其使用方法
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
IL297919A (en) * 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN107427557B (zh) * 2014-08-13 2022-01-04 费城儿童医院 用于包装和表达变体因子viii以治疗血友病的改良表达组件
EP3294309A4 (en) 2015-05-14 2019-01-16 St. Jude Children's Research Hospital, Inc. NUCLEIC ACID MOLECULES WITH SPACERS AND METHOD FOR USE THEREOF

Similar Documents

Publication Publication Date Title
JP2021184734A5 (https=)
Li et al. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences
Uno et al. Arabidopsis basic leucine zipper transcription factors involved in an abscisic acid-dependent signal transduction pathway under drought and high-salinity conditions
Whitehouse et al. Antagonistic forces that position nucleosomes in vivo
JP2018515102A5 (https=)
HRP20241180T1 (hr) Modificirani faktor ix, te pripravci, postupci i upotreba za prijenos gena u stanice, organe i tkiva
Suzuki et al. Rice MYB protein OSMYB5 specifically binds to the AACA motif conserved among promoters of genes for storage protein glutelin
JP7796702B2 (ja) スペーサーを含む核酸分子およびその使用の方法
Wang et al. Impact of different promoters on episomal vectors harbouring characteristic motifs of matrix attachment regions
Richardson et al. Requirement for either early region 1a or early region 1b adenovirus gene products in the helper effect for adeno-associated virus
JP2021534814A5 (https=)
Suzuki et al. Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position
Cooper Muscle-specific splicing of a heterologous exon mediated by a single muscle-specific splicing enhancer from the cardiac troponin T gene
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
CN102234647B (zh) 一个水稻逆境诱导启动子kt619p的鉴定和应用
Buvoli et al. Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors
Haun et al. Characterization of the human ADP-ribosylation factor 3 promoter. Transcriptional regulation of a TATA-less promoter.
Strauss et al. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53
CN116981776A (zh) 使用合成启动子控制多基因表达
Astell et al. Sequence of the 3′ terminus of the genome from kilham rat virus, a nondefective parvovirus
CN102725408B (zh) 猪肌抑素基因启动子及其应用
Rockhold et al. Structure of two Solanum bulbocastanum polyubiquitin genes and expression of their promoters in transgenic potatoes
Kucharova et al. Design and optimization of short DNA sequences that can be used as 5′ fusion partners for high-level expression of heterologous genes in Escherichia coli
Forde AT-rich elements (ATREs) in the promoter regions of nodulin and other higher plant genes: a novel class of cis-acting regulatory element?
CN103194450A (zh) 一种提高肌细胞生成素(MyoG)基因启动子活性的方法